PEPGEN INC (PEPG)

Company Profile

PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. The company also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Company Info

PEPGEN INC

245 Main St, 2nd Floor

Cambridge MASSACHUSETTS

P: 17034568000

Employees: 64

Website: https://pepgen.com